| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
I-bu-rG Phosphoramidite does not have a specific biological target as it is a synthetic building block for RNA synthesis. Its role is to serve as a protected guanosine monomer for the synthesis of RNA oligonucleotides. The TBDMS and iBu protecting groups allow for selective deprotection during RNA synthesis.
|
|---|---|
| ln Vitro |
In vitro activity is not applicable to I-bu-rG Phosphoramidite as it is a synthetic intermediate. Its utility is demonstrated in its ability to be incorporated into RNA oligonucleotides through solid-phase synthesis. The compound's purity ensures high-quality oligonucleotide synthesis for molecular biology applications.
|
| ln Vivo |
In vivo activity is not applicable to I-bu-rG Phosphoramidite as it is a chemical reagent for research use only, not a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not performed for I-bu-rG Phosphoramidite, as it is a synthetic intermediate. Its characterization typically involves chemical analysis methods such as HPLC, NMR, and mass spectrometry.
|
| Cell Assay |
In vitro cellular assays are not applicable to I-bu-rG Phosphoramidite. The compound is used exclusively in chemical synthesis reactions for the production of RNA oligonucleotides.
|
| Animal Protocol |
In vivo animal experiments are not applicable to I-bu-rG Phosphoramidite.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not applicable to I-bu-rG Phosphoramidite as it is a synthetic intermediate, not a therapeutic agent.
|
| Toxicity/Toxicokinetics |
I-bu-rG Phosphoramidite is not intended for human therapeutic use, and toxicological data are not applicable as it is a research chemical.
|
| Additional Infomation |
I-bu-rG Phosphoramidite (2'-O-TBDMS-iBu-rG Phosphoramidite) (CAS#: 147201-04-5) is a modified phosphoramidite monomer used for RNA synthesis. It features TBDMS and iBu protecting groups. It is for research use only.
|
| Molecular Formula |
C50H68N7O9PSI
|
|---|---|
| Molecular Weight |
970.18
|
| Exact Mass |
969.458
|
| CAS # |
147201-04-5
|
| PubChem CID |
135587729
|
| Appearance |
Solid powder
|
| LogP |
12.44
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
68
|
| Complexity |
1690
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(C)C(=O)NC1=NC2=C(C(=O)N1)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COC(C4=CC=CC=C4)(C5=CC=C(C=C5)OC)C6=CC=C(C=C6)OC)OP(N(C(C)C)C(C)C)OCCC#N)O[Si](C)(C)C(C)(C)C
|
| InChi Key |
PGJKESPHANLWME-FTZVBZPOSA-N
|
| InChi Code |
InChI=1S/C50H68N7O9PSi/c1-32(2)45(58)54-48-53-44-41(46(59)55-48)52-31-56(44)47-43(66-68(12,13)49(7,8)9)42(65-67(63-29-17-28-51)57(33(3)4)34(5)6)40(64-47)30-62-50(35-18-15-14-16-19-35,36-20-24-38(60-10)25-21-36)37-22-26-39(61-11)27-23-37/h14-16,18-27,31-34,40,42-43,47H,17,29-30H2,1-13H3,(H2,53,54,55,58,59)/t40-,42-,43-,47-,67?/m1/s1
|
| Chemical Name |
N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-[tert-butyl(dimethyl)silyl]oxy-4-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxyoxolan-2-yl]-6-oxo-1H-purin-2-yl]-2-methylpropanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (103.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0307 mL | 5.1537 mL | 10.3074 mL | |
| 5 mM | 0.2061 mL | 1.0307 mL | 2.0615 mL | |
| 10 mM | 0.1031 mL | 0.5154 mL | 1.0307 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
